These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Gene therapy for hemophilia: advancing beyond the first clinical success. Monahan PE; Gui T Curr Opin Hematol; 2013 Sep; 20(5):410-6. PubMed ID: 23852185 [TBL] [Abstract][Full Text] [Related]
5. New developments in the treatment of pediatric hemophilia and bleeding disorders. Branchford BR; Monahan PE; Di Paola J Curr Opin Pediatr; 2013 Feb; 25(1):23-30. PubMed ID: 23274430 [TBL] [Abstract][Full Text] [Related]
6. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Monahan PE; Samulski RJ; Tazelaar J; Xiao X; Nichols TC; Bellinger DA; Read MS; Walsh CE Gene Ther; 1998 Jan; 5(1):40-9. PubMed ID: 9536263 [TBL] [Abstract][Full Text] [Related]
7. Gene therapy in an era of emerging treatment options for hemophilia B. Monahan PE J Thromb Haemost; 2015 Jun; 13 Suppl 1(0 1):S151-60. PubMed ID: 26149016 [TBL] [Abstract][Full Text] [Related]
9. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia. High KA Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929 [TBL] [Abstract][Full Text] [Related]
10. Functions of AAV-CMV-F.IX And AAV-EF1alpha-F.IX in gene therapy for hemophilia B. Wiwanitkit V Hum Gene Ther; 2007 Feb; 18(2):89-92. PubMed ID: 17266422 [TBL] [Abstract][Full Text] [Related]
11. Inherited disorders of hemostasis in dogs and cats. Barr JW; McMichael M Top Companion Anim Med; 2012 May; 27(2):53-8. PubMed ID: 23031456 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus serotype 1 vector. Liu YL; Mingozzi F; Rodriguéz-Colôn SM; Joseph S; Dobrzynski E; Suzuki T; High KA; Herzog RW Hum Gene Ther; 2004 Aug; 15(8):783-92. PubMed ID: 15319035 [TBL] [Abstract][Full Text] [Related]
13. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787 [TBL] [Abstract][Full Text] [Related]
14. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793 [TBL] [Abstract][Full Text] [Related]
15. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Wang L; Nichols TC; Read MS; Bellinger DA; Verma IM Mol Ther; 2000 Feb; 1(2):154-8. PubMed ID: 10933925 [TBL] [Abstract][Full Text] [Related]
16. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects. Hasbrouck NC; High KA Gene Ther; 2008 Jun; 15(11):870-5. PubMed ID: 18432276 [TBL] [Abstract][Full Text] [Related]